Last updated: September 8, 2026
Morphine sulfate/naltrexone hydrochloride is best known as Embeda, an extended-release opioid capsule developed by King Pharmaceuticals and later commercialized by Pfizer. The product combines morphine sulfate for analgesia with sequestered naltrexone hydrochloride intended to reduce the effect of injected or crushed abuse. Its commercial trajectory has been constrained by the decline in long-term opioid prescribing, safety restrictions, competition from generic morphine, and the limited revenue disclosure available for the product after Pfizer acquired King.
What drug contains morphine sulfate and naltrexone hydrochloride?
Embeda contains extended-release morphine sulfate with naltrexone hydrochloride in a multiparticulate formulation. It was approved by the U.S. Food and Drug Administration in 2009 under NDA 022321 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment when alternatives are inadequate.[1]
The product is distinct from:
- Immediate-release morphine sulfate tablets, solutions, and injections.
- Standard extended-release morphine sulfate products such as MS Contin.
- Naltrexone hydrochloride products used independently for alcohol or opioid dependence.
- Buprenorphine-based medications used for opioid use disorder.
- Abuse-deterrent oxycodone and hydrocodone formulations.
The product’s commercial rationale was formulation-based. Naltrexone was physically sequestered in the capsule. When the dosage form was swallowed intact, the naltrexone was intended to remain unavailable. Crushing or dissolving the product could release naltrexone along with morphine, potentially reducing opioid effects and creating a deterrent to manipulation.[1]
What was Embeda’s FDA regulatory status?
Embeda received FDA approval in August 2009. The original approval followed earlier regulatory concerns related to the product’s naltrexone-release characteristics and manufacturing controls. FDA-approved labeling warns that tampering can result in rapid release of morphine and naltrexone, with risks including overdose, withdrawal, and death.[1]
FDA later recognized Embeda as an abuse-deterrent opioid under its abuse-deterrent opioid labeling framework. Abuse deterrence does not eliminate addiction, overdose, diversion, or tampering risk, and it does not establish that a product is abuse-proof.[2]
Public FDA records have identified Embeda as discontinued from commercial distribution. FDA’s discontinued-drug designation does not by itself mean that the product was withdrawn for safety or efficacy reasons. It indicates that the product is no longer being marketed under the relevant application status.[3]
When did morphine sulfate/naltrexone lose market exclusivity?
Embeda’s commercial exclusivity has been exposed to several different patent and regulatory clocks rather than one single expiration date.
| Exclusivity category |
Relevance to Embeda |
| FDA approval |
Approved in 2009 under NDA 022321 |
| New chemical entity exclusivity |
Not the primary commercial protection because morphine and naltrexone were established active ingredients |
| Formulation patents |
Potentially relevant to the extended-release and abuse-deterrent design |
| Method-of-use patents |
Could cover use in opioid-tolerant patients or pain treatment |
| Orphan exclusivity |
Not applicable to the broad chronic-pain indication |
| Pediatric exclusivity |
No generally cited six-month pediatric extension is associated with the core commercial history |
| Generic substitution |
Dependent on approved ANDAs, bioequivalence, labeling, and enforceable patents |
The commercial value of Embeda depended mainly on formulation protection and the ability to differentiate the product from inexpensive morphine sulfate. Once generic or alternative extended-release opioid options were available, the product’s premium pricing became difficult to sustain.
What patents protect morphine sulfate/naltrexone hydrochloride?
The relevant intellectual-property estate has historically centered on abuse-deterrent extended-release opioid formulations rather than on new chemical entities.
King Pharmaceuticals and affiliated entities pursued patents covering controlled-release morphine formulations containing an opioid antagonist, including naltrexone. Patent families associated with such products generally addressed:
- Multiparticulate or bead-based dosage forms.
- Controlled release of morphine sulfate.
- Sequestration of naltrexone.
- Release of naltrexone after crushing, chewing, dissolving, or other manipulation.
- Dosage forms designed for oral administration to opioid-tolerant patients.
- Manufacturing and coating processes for the beads or pellets.
The relevant patent analysis must be conducted patent-by-patent. A patent covering the concept of combining morphine and naltrexone does not necessarily block every extended-release morphine product, and a patent claim may be limited by specific ratios, coatings, release profiles, particle structures, or manufacturing steps.
How strong was the Embeda patent estate?
The estate was commercially meaningful but structurally vulnerable.
Its strengths were:
- The product used a technically differentiated delivery system rather than a simple combination tablet.
- Formulation claims could create a barrier to direct substitution if they covered the commercial capsule architecture.
- Manufacturing know-how involving antagonist sequestration and controlled release could be difficult to reproduce without process development.
Its weaknesses were:
- Morphine sulfate and naltrexone hydrochloride were both established compounds.
- The product competed against low-cost morphine products with much simpler regulatory and manufacturing profiles.
- A generic applicant could potentially avoid particular formulation claims by using a different release design.
- Abuse-deterrent labeling does not guarantee higher reimbursement or durable physician demand.
- The total opioid market contracted after regulatory and payer restrictions intensified.
The estate therefore had stronger technical differentiation than ordinary morphine products but weaker long-term commercial leverage than a protected new chemical entity.
Were there Paragraph IV challenges to Embeda?
Publicly available regulatory and litigation records do not establish a broad, commercially successful wave of Paragraph IV generic launches for Embeda comparable with major blockbuster products. The absence of a visible generic launch does not necessarily mean that all patents were strong. It can also reflect limited market opportunity, manufacturing complexity, insufficient expected return, or the small size of the branded market.
A Paragraph IV applicant would have had to address several issues:
- Whether the proposed product was therapeutically equivalent to Embeda.
- Whether the generic product used the same abuse-deterrent architecture.
- Whether listed formulation or method patents were valid and infringed.
- Whether the product could satisfy FDA requirements for abuse-deterrent labeling.
- Whether the expected price and volume justified formulation development.
For a low-volume opioid product, these development costs can be difficult to recover. The commercial decision may favor avoiding a direct Embeda challenge and pursuing ordinary morphine products or opioid-use-disorder therapies instead.
What formulation patents protect the product?
The formulation is the principal technical asset. Embeda’s design used extended-release morphine with naltrexone incorporated into the dosage form. The intended commercial effect was selective release:
- Intact oral administration: sustained morphine release with limited naltrexone exposure.
- Crushing or manipulation: release of naltrexone intended to reduce opioid effect and deter abuse.
- Injection or dissolution: elevated risk of naltrexone exposure, opioid withdrawal, and other serious effects.
This creates a more complex development profile than standard morphine sulfate extended-release capsules. A competing product would need to demonstrate reproducible pharmacokinetics, dose proportionality, stability, tamper-response characteristics, and manufacturing consistency.
The principal IP barrier is therefore a combination of patent claims, manufacturing expertise, clinical pharmacology, and FDA labeling requirements. None of these barriers alone guarantees market protection.
What is the competitive landscape for morphine sulfate/naltrexone?
Embeda competes in three overlapping markets.
Extended-release opioid analgesics
The main competitors include:
- MS Contin and generic extended-release morphine sulfate.
- OxyContin and generic extended-release oxycodone.
- Xtampza ER.
- Hysingla ER.
- Opana ER before its withdrawal from the U.S. market.
- Exalgo and generic hydromorphone extended-release products.
Morphine has a significant cost advantage because it is a mature generic molecule. Embeda therefore needed to justify a premium through abuse-deterrent positioning, clinical utility, and payer coverage.
Abuse-deterrent opioids
Abuse-deterrent competitors include oxycodone and hydrocodone products with labeling based on physical or chemical resistance to manipulation. These products compete for a shrinking chronic-pain market and often face reimbursement restrictions.
Non-opioid and opioid-sparing therapies
Long-term opioid prescribing has faced pressure from FDA warnings, CDC guidance, state limits, payer controls, and institutional prescribing policies. NSAIDs, acetaminophen, anticonvulsants, antidepressants, physical therapy, interventional procedures, and buprenorphine-based approaches reduce the addressable market for chronic opioid analgesics.[4]
How did opioid regulation affect Embeda revenue?
The product launched into a market that later experienced sustained pressure from opioid litigation, tighter prescribing controls, abuse surveillance, and payer utilization management.
Key market forces included:
| Market force |
Effect on Embeda |
| Declining chronic opioid prescribing |
Reduced eligible patient population |
| Generic morphine availability |
Limited pricing power |
| Abuse-deterrent formulation requirements |
Increased development and manufacturing costs |
| FDA opioid labeling and safety communications |
Reduced prescribing confidence |
| State and federal prescribing limits |
Reduced treatment duration and volume |
| Payer prior authorization |
Increased access friction |
| Opioid litigation and settlement costs |
Raised commercial and reputational risk |
| Alternative pain therapies |
Reduced long-term opioid demand |
The abuse-deterrent feature supported product differentiation but did not create a separate reimbursement category. FDA has stated that abuse-deterrent formulations are expected to reduce abuse by specific routes, not prevent opioid misuse or addiction.[2]
What was Pfizer’s financial exposure to Embeda?
Pfizer did not report Embeda as a separately material product in its public financial statements. Pfizer acquired King Pharmaceuticals in 2011, bringing Embeda and other pain products into Pfizer’s portfolio.[5]
Pfizer’s financial exposure was therefore indirect and limited by portfolio scale. The company’s public reporting generally grouped products within broader business segments and did not provide a recurring standalone revenue series for Embeda. That prevents a reliable public calculation of:
- Annual Embeda revenue.
- Embeda gross margin.
- Product-level operating profit.
- Revenue lost after discontinuation.
- Product-specific impairment charges.
- Net settlement or litigation cost allocation.
The commercial trajectory can still be characterized:
- King developed and launched Embeda as a differentiated opioid product.
- Pfizer acquired King and inherited the product and its opioid-market exposure.
- The U.S. opioid market became more regulated and commercially constrained.
- Embeda’s premium formulation faced competition from generic morphine and other abuse-deterrent products.
- The product was later discontinued from commercial distribution.
- Pfizer did not identify Embeda as a material standalone growth driver in public reporting.
What litigation and settlement agreements affected the product?
The major legal risk was sector-wide opioid litigation rather than a clearly identified, product-specific patent dispute that reshaped Embeda’s market.
Pharmaceutical companies, distributors, pharmacies, and manufacturers faced extensive federal, state, local, and tribal claims concerning opioid marketing, distribution, monitoring, and alleged public-health damage. Pfizer’s opioid exposure included legacy products associated with King Pharmaceuticals. Pfizer disclosed opioid-related legal matters and settlement obligations in its filings, but public company reporting did not allocate those obligations specifically to Embeda.[6]
Patent litigation risk would have depended on any ANDA filing and the patents listed for the product. A generic challenge could have produced a 30-month stay under the Hatch-Waxman Act if the statutory conditions were met, but a widely reported market-shifting Embeda patent settlement is not established in the principal public sources reviewed.
What generic launch scenarios exist for morphine sulfate/naltrexone?
Three scenarios define the product’s remaining commercial logic.
Scenario 1: No direct generic launch
This is the most commercially plausible outcome where the branded product has limited demand and the generic must replicate a complex formulation. Ordinary generic morphine remains available, reducing the incentive to develop a direct Embeda substitute.
Scenario 2: Direct generic abuse-deterrent capsule
A generic entrant could target the same reference product if it can establish bioequivalence and meet FDA requirements. The likely result would be rapid price erosion because the market is mature and prescribers have multiple opioid alternatives.
Scenario 3: Alternative abuse-deterrent formulation
A competitor could develop a different opioid-antagonist or tamper-resistant design. This would avoid some Embeda-specific claims but require new formulation work, clinical development, and regulatory positioning. The commercial return would depend on reimbursement and the size of the remaining chronic-pain market.
How does Embeda compare with standard extended-release morphine?
| Attribute |
Morphine sulfate/naltrexone |
Standard extended-release morphine |
| Active analgesic |
Morphine sulfate |
Morphine sulfate |
| Antagonist |
Sequestered naltrexone hydrochloride |
None |
| Formulation complexity |
High |
Moderate to low |
| Intended differentiation |
Abuse deterrence |
Extended analgesia |
| Manufacturing burden |
Higher |
Lower |
| Generic competition |
More technically complex |
Extensive |
| Pricing power |
Historically premium-oriented |
Generally commodity-oriented |
| Regulatory risk |
Abuse-deterrent and opioid safety requirements |
Opioid safety requirements |
| Long-term market outlook |
Constrained |
Stable but pressured by generic pricing |
The combination offered more formulation differentiation but did not change the underlying dependence on morphine demand. As prescribing shifted toward lower opioid exposure and non-opioid treatment, the technical advantage had less commercial leverage.
How strong is the long-term market outlook?
The long-term outlook is weak for a branded morphine/naltrexone product in the United States. The market has four structural constraints:
- Morphine sulfate is widely available at low generic prices.
- Chronic opioid prescribing remains under regulatory and payer pressure.
- Abuse-deterrent labeling does not ensure market preference.
- The product has no publicly disclosed standalone revenue base supporting continued commercial investment.
The strongest residual value lies in formulation know-how, patent remnants, manufacturing processes, and possible licensing of abuse-deterrent delivery technology. The weakest value lies in direct branded commercialization for chronic pain.
Key Takeaways
- Morphine sulfate/naltrexone hydrochloride is primarily associated with Embeda, an extended-release opioid capsule approved by FDA in 2009.
- Its differentiation came from sequestered naltrexone intended to deter crushing, dissolving, and injection.
- The product relied mainly on formulation and manufacturing IP, not new-molecule exclusivity.
- FDA records identify Embeda as discontinued from commercial distribution.
- Pfizer inherited Embeda through its acquisition of King Pharmaceuticals but did not publicly report a material standalone revenue stream.
- Generic morphine, opioid prescribing restrictions, payer controls, and non-opioid therapies weakened the product’s commercial position.
- Public sources do not establish a major, market-defining Paragraph IV settlement or generic launch for Embeda.
- The product’s remaining strategic value is more likely to reside in formulation technology than in U.S. branded sales.
FAQs
Is morphine sulfate/naltrexone the same as naltrexone for addiction treatment?
No. Embeda contains naltrexone as a sequestered component in an extended-release morphine formulation. Standalone naltrexone products are used for alcohol dependence and relapse prevention after opioid detoxification.
Does Embeda prevent opioid addiction?
No. Its formulation was designed to deter certain forms of tampering and abuse. It does not eliminate dependence, addiction, overdose, diversion, or misuse.
Is Embeda still available in the United States?
FDA public records identify Embeda as discontinued from commercial distribution. Standard morphine sulfate products remain available through generic and other extended-release formulations.
Could a generic company copy the Embeda formulation?
A generic applicant would need to satisfy FDA requirements for pharmaceutical equivalence or therapeutic equivalence, address listed patents, and reproduce the relevant release and abuse-deterrent characteristics. A different formulation could avoid some claims but would require separate development and regulatory support.
Does naltrexone increase the value of an extended-release morphine product?
It can create technical differentiation, but commercial value depends on physician adoption, payer coverage, abuse-deterrent recognition, manufacturing cost, patent life, and the overall size of the chronic opioid market. Those factors limited Embeda’s long-term financial trajectory.
References
-
U.S. Food and Drug Administration. (2009). Embeda prescribing information: Morphine sulfate and naltrexone hydrochloride extended-release capsules.
-
U.S. Food and Drug Administration. (2015). Abuse-deterrent opioid analgesics: Guidance for industry.
-
U.S. Food and Drug Administration. (n.d.). Drugs@FDA: Embeda, NDA 022321.
-
Centers for Disease Control and Prevention. (2022). CDC clinical practice guideline for prescribing opioids for pain.
-
Pfizer Inc. (2011). Annual report for the fiscal year ended December 31, 2010.
-
Pfizer Inc. (2024). Annual report for the fiscal year ended December 31, 2023.
